Importantly, silencing FBXO21 delayed disease onset of NSG mice following transplantation in comparison to mice transplanted with the shNTC in patient derived cell lines, consistent with survival in human AML patients with low FBXO21 expression (Fig. 2J, and Supplementary Fig. 1F). This evidence concerns the gene FBXO21 and acute myeloid leukemia.